Brimonidine Tartrate for the Treatment of Injection Related Erythema Associated With Sub-cutaneous Administration of Peginterferon Beta-1a (BRITE)

Trial Profile

Brimonidine Tartrate for the Treatment of Injection Related Erythema Associated With Sub-cutaneous Administration of Peginterferon Beta-1a (BRITE)

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 29 Apr 2016

At a glance

  • Drugs Brimonidine (Primary) ; Peginterferon beta-1a
  • Indications Erythema; Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms BRITE
  • Sponsors Biogen
  • Most Recent Events

    • 27 Apr 2016 The trial status is "Prematurely ended" in Netherlands.
    • 21 Apr 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 12 Feb 2016 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top